BRIEF: BrainAurora’s revenue nearly doubles but loss widens in first half of 2025

BrainAurora Medical Technology Ltd. (6681.HK) announced on Thursday that its revenue surged 92.8% year-on-year to 100 million yuan ($14 million) in the first half of this year. But the maker of cognitive impairment digital therapeutics fell further into the red as its net loss grew by 11% to 127 million yuan during the period.

The company attributed the strong revenue growth to more hospitals purchasing its cognitive impairment digital therapy system, with the number rising from 186 a year earlier to 205 in the latest six-month period. Patient usage also increased from about 1.8 million sessions to 2.59 million, while the number of patients using the system at home grew to 12,915. In addition, the company’s medical AI large language model solutions contributed over 240 million yuan in revenue, becoming a new growth driver. But higher sales costs, administrative expenses, and R&D spending dragged down the company’s overall profitability.

In June, Dr. Wang Xiaoyi resigned as the company’s executive director, CEO and chief R&D officer due to depression.

BrainAurora’s stock opened flat on Friday, closing at HK$5.36 by the midday break, down 1.89%.

By Lee Shih Ta

To subscribe to Bamboo Works weekly free newsletter, click here